Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 1, 2008The OncologistOpen Access

Metastatic Pancreatic Cancer 2008: Is the Glass Less Empty?

View Full Paper
Ask AI
Bookmark
Share

Authors

JNJacqueline NietoMGMichael L. GrossbardNYU Langone HealthPKPeter KozuchMount Sinai Hospital

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Nieto et al. (2008) studied this question.

synapsesocial.com/papers/6a835864b36623e7bea0f91ahttps://doi.org/10.1634/theoncologist.2007-0181
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Phase II Study of Oral Capecitabine in Patients With Advanced or Metastatic Pancreatic Cancer2002 · 186 citations
  2. 2A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.1991 · 765 citations
  3. 3Pooled efficacy analysis from a phase I–II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer2007 · 20 citations